Aquestive Therapeutics
AQST
60 hedge funds and large institutions have $62M invested in Aquestive Therapeutics in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 25 closing their positions.
38% more call options, than puts
Call options by funds: $592K | Put options by funds: $428K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.23% less ownership
Funds ownership: 45.93% → 42.7% (-3.2%)
6% less funds holding
Funds holding: 64 → 60 (-4)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
28% less capital invested
Capital invested by funds: $86.4M → $62M (-$24.4M)
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.75M |
| 2 |
Renaissance Technologies
New York
|
+$980K |
| 3 |
CCM
CAAS Capital Management
New York
|
+$867K |
| 4 |
Morgan Stanley
New York
|
+$782K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$757K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.02M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.97M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.01M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$667K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$540K |
AQST Hedge Fund Activity: Q2 2021 in Review
60 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2021, worth a combined $62M — down 28% from $86.4M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of AQST and 21 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.75M. The largest seller was BlackRock, cutting an estimated $4.02M.
- 60 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2021, down from 64 in Q1 2021.
- Funds reported $62M of Aquestive Therapeutics stock for Q2 2021, down 28% quarter-over-quarter.
- 21 funds opened new Aquestive Therapeutics positions in Q2 2021 and 25 closed out, a net change of -4 holders.
- The largest Aquestive Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $1.75M added.
- The largest Aquestive Therapeutics seller in Q2 2021 was BlackRock, an estimated $4.02M sold.
Based on aggregated 13F filings for Q2 2021.